We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Center for Neurodegenerative Disorders (CENDIVE)

Alan Lerner, MD
Alan J. Lerner, MD

The vision of CENDIVE is to be the leader in the discovery of basic mechanisms underlying neurodegenerative disorders and development of early stage pharmaceutical development, primarily for symptomatic Alzheimer’s disease (AD) patients. CENDIVE will reach its goals through aligning its mission with UH, the Neurological Institute and the Cleveland Brain Health Initiative. This investment in clinical neurodegenerative disorders will help UH physicians to be at the forefront of American medicine.

An immediate priority for the center is to support the recently NIH-funded Cleveland Alzheimer’s Disease Research Center, a collaboration between UH, Cleveland Clinic Foundation, Case Western Reserve University, and the VA hospital. The program is closely allied with a unique translational therapeutics core based at the Harrington Discover Institute (HDI) and will work with other existing resources such as the National Prion Disease Surveillance.

CENDIVE will develop innovative programming in population health across the UH system by working with the Accountable Care Organization (ACO), strive to increase minority participation in research with the establishment of a Brain Health Clinic at the UH Otis Moss Jr. Health Center, foster industry-academic partnerships, and accelerate treatments for Alzheimer’s disease through early stage clinical drug and biomarker studies. It is anticipated that the CENDIVE’s interdisciplinary approach efforts will lead to development of better outcomes for patients with neurodegenerative disorders.